Ozempic vs Wegovy: Same Drug, Different Purpose

Semaglutide

14.9% body weight lost

In the STEP 1 trial, adults on semaglutide 2.4 mg (Wegovy's dose) lost 14.9% of their body weight over 68 weeks, compared to 2.4% on placebo.

Wilding et al., NEJM, 2021

Wilding et al., NEJM, 2021

View as image

Ozempic and Wegovy are the same molecule. Both contain semaglutide, a GLP-1 receptor agonist manufactured by Novo Nordisk. The difference is regulatory, not chemical: Ozempic is FDA-approved for type 2 diabetes (max dose 2.0 mg/week), while Wegovy is FDA-approved for chronic weight management (max dose 2.4 mg/week, with a 7.2 mg formulation approved in 2026). This distinction matters because it determines insurance coverage, dosing protocols, and which clinical trial data supports each use case. For a complete overview of the science behind this peptide, see our pillar article on semaglutide for weight loss.

The Molecule: What Semaglutide Actually Is

Semaglutide is a synthetic analog of glucagon-like peptide-1 (GLP-1), a hormone naturally released by intestinal L-cells after eating. Natural GLP-1 has a half-life of about 2 minutes because the enzyme DPP-4 degrades it rapidly. Semaglutide was engineered with specific amino acid modifications and a fatty acid chain that binds to albumin, extending its half-life to approximately 7 days.^[2]

This extended half-life is what makes once-weekly dosing possible. When semaglutide binds to GLP-1 receptors in the pancreas, it stimulates insulin secretion and suppresses glucagon release in a glucose-dependent manner. In the brain, it acts on hypothalamic neurons involved in appetite regulation and reward processing, which accounts for its weight-reducing effects. The same molecule produces both effects. The only question is which effect you are primarily targeting.

FDA Approval: Two Brand Names, Two Indications

The regulatory distinction is straightforward:

Ozempic received FDA approval in December 2017 for adults with type 2 diabetes to improve glycemic control alongside diet and exercise. It is available in injectable doses of 0.25 mg, 0.5 mg, 1.0 mg, and 2.0 mg per week. Singh et al. (2022) reviewed how the GLP-1 class evolved from diabetes medications to weight management tools.^[1]

Wegovy received FDA approval in June 2021 specifically for chronic weight management in adults with a BMI of 30 or greater (or 27 or greater with at least one weight-related comorbidity). Its dosing escalates from 0.25 mg to a maintenance dose of 2.4 mg per week. In 2026, the FDA approved Wegovy HD at 7.2 mg per week, offering a higher dose option for patients who need more aggressive weight management.

The off-label use of Ozempic for weight loss has been widespread. Many prescribers write Ozempic prescriptions for patients seeking weight loss because Wegovy has faced chronic supply shortages. This practice works pharmacologically (it is the same drug) but raises questions about dosing optimization, since Ozempic's maximum dose of 2.0 mg is lower than Wegovy's therapeutic weight loss dose of 2.4 mg.

The Clinical Trial Evidence: Diabetes (SUSTAIN Program)

Ozempic's approval rests on the SUSTAIN clinical trial program. SUSTAIN-6, published by Marso et al. (2016) in the New England Journal of Medicine, was the landmark cardiovascular outcomes trial.^[2]

The trial enrolled 3,297 patients with type 2 diabetes and high cardiovascular risk. Participants received semaglutide (0.5 mg or 1.0 mg weekly) or placebo for a median of 2.1 years. The primary composite outcome (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) occurred in 6.6% of the semaglutide group versus 8.9% of the placebo group, a 26% relative risk reduction (HR 0.74, 95% CI 0.58-0.95).

Aroda et al. (2023) pooled safety data across the SUSTAIN and PIONEER programs, finding that the most common adverse events were gastrointestinal: nausea (11-20%), diarrhea (5-10%), and vomiting (5-9%). These events were mostly mild to moderate and occurred primarily during the dose-escalation phase.^[3] This GI tolerability profile is consistent across both brand names since the molecule is identical.

The Clinical Trial Evidence: Weight Loss (STEP Program)

Wegovy's approval rests on the STEP clinical trial program. STEP 1, published by Wilding et al. (2021) in the New England Journal of Medicine, established the efficacy of semaglutide 2.4 mg for weight management.^[4]

The trial enrolled 1,961 adults with a BMI of 30 or greater (or 27 or greater with at least one weight-related comorbidity) who did not have diabetes. After 68 weeks, the semaglutide group lost 14.9% of their body weight compared to 2.4% in the placebo group. A total of 86.4% of participants on semaglutide achieved at least 5% weight loss, and 69.1% achieved at least 10%. For context on how much weight loss is typical, see our dedicated analysis.

STEP 5, published by Garvey et al. (2022), extended the evidence to two years.^[5] At 104 weeks, participants maintained an average weight loss of 15.2% with semaglutide 2.4 mg versus 2.6% with placebo. The sustained effect over two years was important because many weight loss interventions show initial results that fade with time. Semaglutide did not follow that pattern while patients remained on treatment.

The Dosing Difference: Why 0.4 mg Matters

The maximum dose gap between Ozempic (2.0 mg) and Wegovy (2.4 mg) is not trivial. Fatima et al. (2024) conducted a comparative analysis of different semaglutide doses and found dose-dependent effects on weight reduction.^[6]

STEP 8, published by Rubino et al. (2022), directly compared semaglutide 2.4 mg to liraglutide 3.0 mg (Saxenda) in a head-to-head trial.^[7] In 338 adults with overweight or obesity, semaglutide 2.4 mg produced 15.8% weight loss at 68 weeks versus 6.4% for liraglutide 3.0 mg. This trial used the Wegovy dose, not the Ozempic dose.

The dose-escalation schedule also differs. Ozempic escalates over 8 weeks (0.25 mg for 4 weeks, then 0.5 mg). Wegovy escalates over 16 weeks through five dose levels (0.25, 0.5, 1.0, 1.7, 2.4 mg), each held for 4 weeks. The slower escalation was designed to reduce the gastrointestinal side effects that are most prominent during dose increases. For details on this protocol, see our article on semaglutide dose escalation.

Cardiovascular Protection Beyond Diabetes

The SELECT trial, published by Lincoff et al. (2023) in the New England Journal of Medicine, changed the landscape by showing cardiovascular benefits in patients with obesity who did not have diabetes.^[8]

This massive trial enrolled 17,604 adults aged 45 and older with established cardiovascular disease and a BMI of 27 or greater, but without diabetes. Semaglutide 2.4 mg reduced the primary composite cardiovascular endpoint by 20% (HR 0.80, 95% CI 0.72-0.90). This was the first trial to demonstrate that a GLP-1 agonist could reduce cardiovascular events in people without diabetes, based on its weight loss effects and likely anti-inflammatory properties.

SELECT used the Wegovy dose (2.4 mg), not the Ozempic dose. Whether the 2.0 mg dose would produce similar cardiovascular protection in non-diabetic patients has not been tested in a dedicated outcomes trial. This matters for the off-label Ozempic prescribing pattern: the cardiovascular evidence supporting weight-loss use specifically comes from the higher dose.

What Happens When You Stop

One of the most important findings for both Ozempic and Wegovy users comes from the STEP 1 extension study. Wilding et al. (2022) followed participants after they stopped semaglutide 2.4 mg treatment.^[9]

One year after discontinuation, participants had regained two-thirds of their prior weight loss. They had lost an average of 17.3% of body weight on treatment; one year later, they had regained to a net loss of only 5.6%. Cardiometabolic improvements in blood pressure, lipids, and waist circumference similarly reversed.

This finding applies equally to both brand names because the molecule and the biology are the same. Semaglutide does not cure obesity; it manages it. When the drug is removed, the biological drivers of weight regain (increased appetite, reduced energy expenditure, hormonal adaptations) reassert themselves. For a deeper look at this phenomenon, see what happens when you stop taking semaglutide.

Oral Semaglutide: A Third Option

The semaglutide landscape expanded further with the OASIS 1 trial. Knop et al. (2023) tested oral semaglutide 50 mg taken once daily for weight loss in adults without diabetes.^[10]

In 667 participants, oral semaglutide 50 mg produced 15.1% weight loss at 68 weeks versus 2.4% for placebo.^[10] This is comparable to the injectable 2.4 mg results from STEP 1. The oral formulation uses SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) as an absorption enhancer, raising gastric pH locally to protect semaglutide from enzymatic degradation.

Currently, the oral formulation for weight loss is branded as Wegovy (oral), approved at 25 mg and 50 mg daily doses. The earlier oral semaglutide product (Rybelsus) was approved only for type 2 diabetes at doses up to 14 mg.

Which One Is "Better"?

The answer depends entirely on the clinical context:

For type 2 diabetes management, Ozempic has the regulatory approval, the SUSTAIN trial evidence, and the established dosing protocol. The cardiovascular outcomes data from SUSTAIN-6 supports its use in patients with high cardiovascular risk.

For weight management in patients without diabetes, Wegovy has the regulatory approval, the STEP trial evidence at the higher 2.4 mg dose, and the SELECT trial cardiovascular data that specifically studied non-diabetic patients with obesity.

For patients using off-label Ozempic for weight loss, the evidence base is borrowed from Wegovy trials. The maximum Ozempic dose (2.0 mg) is 17% lower than the dose studied in STEP 1-5 and SELECT. Whether this dose difference meaningfully affects outcomes has not been directly tested, but the dose-response data suggests it would produce somewhat less weight loss.

For patients who prefer oral administration, the Wegovy oral formulation and the diabetes-focused Rybelsus provide non-injectable options at different doses and for different indications.

The molecule is identical. The difference is the label, the dose, the insurance pathway, and which clinical trials justify each use. For a comparison with the newer dual-agonist drugs, see our article on how tirzepatide's dual mechanism differs from single GLP-1 agonists.

The Bottom Line

Ozempic and Wegovy contain the same semaglutide molecule but serve different regulatory purposes. Ozempic is approved for type 2 diabetes at up to 2.0 mg weekly, backed by the SUSTAIN trials. Wegovy is approved for chronic weight management at up to 2.4 mg weekly (7.2 mg as of 2026), backed by the STEP trials and the SELECT cardiovascular outcomes trial. The clinical evidence for weight loss and cardiovascular protection in non-diabetic patients comes exclusively from the higher Wegovy dose.

Frequently Asked Questions

What is the difference between Ozempic and Wegovy?

Both contain semaglutide, a GLP-1 receptor agonist made by Novo Nordisk. The difference is the FDA-approved indication and dosing: Ozempic is approved for type 2 diabetes at up to 2.0 mg weekly, while Wegovy is approved for chronic weight management at up to 2.4 mg weekly (or 7.2 mg with Wegovy HD). The molecule itself is chemically identical.

How much weight can you lose on Wegovy vs Ozempic?

The STEP 1 trial showed 14.9% body weight loss at 68 weeks with semaglutide 2.4 mg (Wegovy's dose) in 1,961 adults with obesity (Wilding et al., NEJM, 2021). No equivalent large-scale weight loss trial has been conducted at Ozempic's maximum 2.0 mg dose in non-diabetic patients. In diabetes trials, weight loss at 1.0 mg was approximately 4-6 kg over 30-56 weeks.

Can I use Ozempic for weight loss instead of Wegovy?

Ozempic is frequently prescribed off-label for weight loss, and the molecule is identical to Wegovy. The main limitation is dosing: Ozempic's maximum dose (2.0 mg) is lower than the 2.4 mg dose used in the weight loss clinical trials. The cardiovascular benefits shown in the SELECT trial (20% reduction in events) were also demonstrated at the 2.4 mg dose, not the 2.0 mg dose.

Do Ozempic and Wegovy have the same side effects?

Yes. Both drugs produce the same side effect profile because they contain the same molecule. Pooled data from the SUSTAIN and PIONEER programs showed the most common adverse events are gastrointestinal: nausea (11-20%), diarrhea (5-10%), and vomiting (5-9%) (Aroda et al., 2023). These events are mostly mild to moderate and concentrated during the dose-escalation phase.

Do you regain weight after stopping Ozempic or Wegovy?

Yes. The STEP 1 extension study found that participants regained two-thirds of their lost weight within one year of discontinuing semaglutide 2.4 mg (Wilding et al., 2022). Average weight loss of 17.3% on treatment declined to only 5.6% net loss one year later. Cardiometabolic improvements also reversed, indicating that semaglutide manages but does not cure obesity.

Is there an oral version of Ozempic or Wegovy?

There are now oral semaglutide options for both diabetes and weight loss. Rybelsus (oral semaglutide up to 14 mg daily) is approved for type 2 diabetes. Wegovy oral (25 mg and 50 mg daily) is approved for weight management. In the OASIS 1 trial, oral semaglutide 50 mg produced 15.1% weight loss at 68 weeks, comparable to the injectable 2.4 mg results (Knop et al., Lancet, 2023).